Zobrazeno 1 - 10
of 613
pro vyhledávání: '"N, Cascinelli"'
Autor:
S. Lukiewcz, A. Schneeberger, F. Belli, Georg Stingl, M. Heerlyn, Toshiaki Saida, J. Ansel, N. Cascinelli, D. Maurer, C. Kuwert, Andrzej Slominski, C. Armstrong
Publikováno v:
Experimental Dermatology. 9:439-451
The treatment of patients with metastasizing melanoma, still one of the most deadly diseases in modern medicine, ranks among the greatest challenges that a clinician has to face. Metastatic melanoma also is one of the most profound sources of clinica
Publikováno v:
The Lancet. 351:793-796
Summary Background The use of elective regional node dissection in patients with cutaneous melanoma without any clinical evidence of metastatic spread is still debated. Our aim was to evaluate the efficacy of immediate node dissection in patients wit
Publikováno v:
Europe PubMed Central
We assessed the antiproliferative effects of human recombinant interferon-alpha2a (IFNalpha2a) and 13-cis-retinoic acid (13cis-RA) on two human melanoma cell lines (JR8 and M14). Both cell lines showed a very modest sensitivity to IFNalpha2a and 13ci
Autor:
E. Marubini, M. Aguilar, M. Greco, R. Saccozzi, Luigi Mariani, N. Cascinelli, A. Luini, U. Veronesi
Publikováno v:
Evidence-based Obstetrics & Gynecology. 5:48-50
Autor:
F. Arienti, C. Clemente, Cecilia Melani, Maria Grazia Bernengo, Mario P. Colombo, J. Sulé-Suso, Robert Foa, N. Cascinelli, A. Prada, Filiberto Belli, Anna Guarini, L. Mascheroni, Maria Teresa Illeni, G. Parmiani
Publikováno v:
Human Gene Therapy. 5:1059-1064
Autor:
F. Belli, F. Arienti, L. Rivoltini, M. Santinami, L. Mascheroni, A. Prada, M. Ammatuna, E. Marchesi, G. Parmiani, N. Cascinelli, M. Vaglini
Publikováno v:
Scopus-Elsevier
Chemoresistant melanoma cells are known to be susceptible in vitro to lymphokine activated killer (LAK) cells. To obtain a high LAK/tumour cell ratio in vivo and avoid systemic toxicity due to interleukin-2 (IL-2), we used IL-2 plus LAK cells in the
Autor:
C. M. Balch, S. Havas, N. Cascinelli, E. R. Farmer, A. B. Ackerman, M. A. Tempero, June K Robinson, D. Guerry, F. B. Askin, R. S. Gilgor, Wallace H. Clark, W. H. Hall, C. Cohen, S. Green, Alfred E. Chang, Emily L. Harris, N. A. Swanson, L. A. Goldsmith, J. P. Dutcher
Publikováno v:
JAMA: The Journal of the American Medical Association. 268:1314-1319
Publikováno v:
World Journal of Surgery. 16:203-213
Node dissection for melanoma remains the most important therapeutic decision for the optimal management of the patient with melanoma. In Australia and in some parts of the United States, the majority of patients with intermediate thickness melanoma (
Autor:
M, Santinami, M, Baldi, G, Tragni, A, Maurichi, D, Moglia, A, Bono, C, Bartoli, R, Patuzzo, E, Pennacchioli, N, Cascinelli
Publikováno v:
Tumori. 89
In the National Cancer Institute and S Pio X Hospital series we registered 981 patients with primary cutaneous melanoma and no evidence of clinically detectable regional node metastases underwent sentinel node (SN) dissection to microscopically defin
Publikováno v:
Annals of surgical oncology. 8
From January 1993 to May 2000, 1062 patients with primary cutaneous melanoma and no evidence of clinically detectable regional node metastases underwent sentinel node (SN) dissection to microscopically define the tumor status of the regional lymph no